Analysis of Fecal DNA Methylation to Detect Gastrointestinal Neoplasia
作者： Takeshi Nagasaka , Noriaki Tanaka , Harry M. Cullings , Dong-Sheng Sun , Hiromi Sasamoto
DOI: 10.1093/JNCI/DJP265
关键词:
摘要: Results Analysis of DNA from tissues showed presence extensive methylation in both gene promoters exclusively advanced gastric and colorectal tumors. The assay successfully identified one or more methylated markers fecal 57.1% patients with cancer, 75.0% 44.4% adenomas, but only 10.6% subjects without neoplastic active diseases (difference, cancer vs undiseased = 46.5%, 95% confidence interval (CI) 24.6% to 68.4%, P < .001; difference, 64.4%, CI 53.5% 75.2%, adenoma 33.8%, 14.2% 53.4%, .001). Conclusions Methylation the RASSF2 SFRP2 is associated gastrointestinal tumors relative non-neoplastic conditions. Our novel provides a possible means noninvasively screen not for also
oup.com
oxfordjournals.org
elsevier.com
cabdirect.org
paperity.org
okayama-u.ac.jp 参考文章(50)
Sui Huang, Donald E. Ingber, The structural and mechanical complexity of cell-growth control. Nature Cell Biology. ,vol. 1, ,(1999) , 10.1038/13043
Francis M. Giardiello, Barbara A. Zehnbauer, Pankaj J. Pasricha, Richard J. Jones, Atul Bedi, James P. Barber, Stanley R. Hamilton, Gauri C. Bedi, Adil J. Akhtar, Inhibition of apoptosis during development of colorectal cancer. Cancer Research. ,vol. 55, pp. 1811- 1816 ,(1995)
Peter A Jones, Peter W Laird, Cancer-epigenetics comes of age Nature Genetics. ,vol. 21, pp. 163- 167 ,(1999) , 10.1038/5947
Zhaohui Huang, Lihua Li, Jinfu Wang, Hypermethylation of SFRP2 as a Potential Marker for Stool-Based Detection of Colorectal Cancer and Precancerous Lesions Digestive Diseases and Sciences. ,vol. 52, pp. 2287- 2291 ,(2007) , 10.1007/S10620-007-9755-Y
SJ Winawer, RH Fletcher, L Miller, F Godlee, MH Stolar, CD Mulrow, SH Woolf, SN Glick, TG Ganiats, JH Bond, L Rosen, JG Zapka, SJ Olsen, FM Giardiello, JE Sisk, R Van Antwerp, C Brown-Davis, DA Marciniak, RJ Mayer, Colorectal cancer screening: Clinical guidelines and rationale Gastroenterology. ,vol. 113, pp. 1422- 1423 ,(1997) , 10.1053/GAST.1997.V112.AGAST970594
T MORIKAWA, J KATO, Y YAMAJI, R WADA, T MITSUSHIMA, Y SHIRATORI, A Comparison of the Immunochemical Fecal Occult Blood Test and Total Colonoscopy in the Asymptomatic Population Gastroenterology. ,vol. 129, pp. 422- 428 ,(2005) , 10.1016/J.GASTRO.2005.05.056
Thomas F. Imperiale, David F. Ransohoff, Steven H. Itzkowitz, Barry A. Turnbull, Michael E. Ross, Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. The New England Journal of Medicine. ,vol. 351, pp. 2704- 2714 ,(2004) , 10.1056/NEJMOA033403
Zohar Levi, Paul Rozen, Rachel Hazazi, Alex Vilkin, Amal Waked, Eran Maoz, Shlomo Birkenfeld, Moshe Leshno, Yaron Niv, A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Annals of Internal Medicine. ,vol. 146, pp. 244- 255 ,(2007) , 10.7326/0003-4819-146-4-200702200-00003
M Endoh, G Tamura, T Honda, N Homma, M Terashima, S Nishizuka, T Motoyama, RASSF2, a potential tumour suppressor, is silenced by CpG island hypermethylation in gastric cancer. British Journal of Cancer. ,vol. 93, pp. 1395- 1399 ,(2005) , 10.1038/SJ.BJC.6602854
D Sidransky, T Tokino, Hamilton, K. Kinzler, B Levin, P Frost, B Vogelstein, Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science. ,vol. 256, pp. 102- 105 ,(1992) , 10.1126/SCIENCE.1566048